Reason for request
Inclusion on the list of medicines reimbursed by National Insurance (B/5 and B/20) and approved for use by hospitals (B/5, B/20 and B/30).
Clinical Benefit
| Low |
the actual benefit of VERSATIS 5% lidocaine plasters in the treatment of PHN is low in view of its weak efficacy demonstrated versus placebo. |
Clinical Added Value
| no clinical added value |
VERSATIS offers no improvement in actual benefit compared to the current treatment strategy (IAB V). |
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
AJ9zBBh8UhaaLYdD
